Description: Manitex Capital Inc. does not have significant business. It focuses on acquiring interests in life sciences, cleantech, and sustainable products/technologies companies. Previously, it was engaged in the acquisition and markets specialty pharmaceutical products, and distributes third-party pharmaceutical products, as well as holds a portfolio in marketable securities. The company is headquartered in Kirkland, Canada.
Home Page: www.manitexcapital.com
MNX Technical Analysis
16667 Hymus Boulevard
Kirkland,
QC
H9H 4R9
Canada
Phone:
514 693 8830
Officers
| Name | Title |
|---|---|
| Mr. Steven Saviuk CA | Chairman, Pres & CEO |
| Ms. Helen Saviuk CA | CFO & Director |
| Mr. Ronald S. Perry CA, CPA | Sec. |
| Mr. Kristof Biniecki | VP of Scientific Affairs - Valeo Pharma Inc |
| Mr. Marc Leger | Exec. VP of Commercial Operations - Valeo Pharma Inc |
| Nathalie Therrien | Vice-Pres of QA & Regulatory Affairs - Valeo Pharma Inc. |
| Mr. Luc Mainville M.B.A, M.B.A. | Sr. VP & CFO of Valeo Pharma Inc |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6444 |
| Price-to-Sales TTM: | 0.4874 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |